Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1384&sort=-other_investigators
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-other_investigators", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1392&sort=-other_investigators", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1385&sort=-other_investigators", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1383&sort=-other_investigators" }, "data": [ { "type": "Grant", "id": "10575", "attributes": { "award_id": "1R43GH002389-01A1", "title": "Rapid COVID-19 Mutation Discrimination Test for Global SARS-CoV-2 Variant Surveillance", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2023-03-31", "award_amount": 275766, "principal_investigator": { "id": 26597, "first_name": "Janet L", "last_name": "Huie", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1947, "ror": "", "name": "JAN BIOTECH, INC.", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Public Health Problem. Covid-19 variant tracking and prevalence is greatly hindered by the lack of quick, high- throughput methods for variant detection. Covid-19 genetic variants are a current and ongoing concern, due to greater transmissibility, morbidity and potential resistance to immunity provided by vaccines. Successful surveillance will likely require full coverage: 100% of people tested (not an extrapolation of sparse or region- specific data). Jan Biotech’s proposed assay quickly detects both known variants and new variants (by detecting unknown sequences through negative results and indicating the need for sequencing) and the probes are easily adapted to detect newly emerging variants of concern and interest. The assay will allow remote and low resource area hospitals and medical centers to quickly and fully assess their community’s SARS-CoV-2 variant index for real-time, evidence-based health mandates. This is both an urgent and very likely a long term need as new variants emerge. Issues with Current Solutions & How Product Meets Unmet Needs. RT-PCR Covid-19 tests provide only a positive or negative result and do not identify genetic variants. Rapid antibody tests for Covid-19 also do not reveal variants. DNA Sequencing of the Covid-19 genome is challenging. The genome is almost 30,000 nucleotides in length and combinations of mutations in different areas of the genome are functional and identifying features of Covid-19 variants. High-throughput RNAseq methods for next-generation sequencing (NGS) require RNA purification, RT-PCR RNAseq library preparation and time-consumptive sequencing and genome assembly. Covid-19 sequencing in any format for identification of variants has not yet been CLIA- or FDA-approved. RT-qPCR assays mined for variant data rely on altered Ct curves, which are nonspecific and can be caused by variations in the assay run. The proposed rapid Covid-19 variant detection and discrimination test, performed in a multiwell plate, is variant-specific and high-throughput. Summary of Approach. We will create RNAamp oligonucleotide-templated photoreduction probe sets specific to the current most prevalent and clinically-significant Covid-19 RNA variants. We will multiplex the Covid-19 variant discrimination RNAamp tests, using different profluorophores for each target and evaluate sensitivity and reliability of multiplex results using negative human saliva samples spiked with multiple Covid-19 variant RNAs. Human samples will be used to assess commercial potential of the multiplexed Covid-19 variant RNAamp test. Covid-19 negative samples will serve as negative controls and the same negative samples spiked with Covid- 19 variant control RNAs will serve as positive controls for each variant test to achieve a statistical correlation of >0.9 with comparison assays as the metric of success. Collaborators and Unique Resources. Jan Biotech, Inc., with expertise in molecular diagnostic development, will obtain human Covid-19 positive and negative test samples from the University of Rochester Medical Center, and, as needed, from Precision for Medicine and BocaBiolistics. Specific Aims Specific Aim 1: Develop multiplexed variant discrimination RNAamp test for Covid-19 strain detection Objective 1.1: Develop and test RNAamp probe sets to differentiate Covid-19 variants of concern. Objective 1.2: Multiplex and test the Covid-19 variant discrimination RNAamp tests. Specific Aim 2: Evaluate variant discrimination RNAamp test on Covid-19 human samples Objective 2.1: Test human samples to assess commercial potential of multiplexed Covid-19 variant RNAamp. Objective 2.2: Statistical determination of assay limit of detection and specificity for each Covid-19 variant will evaluate the utility of the rapid Covid-19 variant discrimination test, including its application to pooled samples. The end result of the project will be a multiplexed Covid-19 variant discrimination test and computational software providing proof-of-concept for Phase II preclinical and clinical evaluation leading towards CLIA or 510(k) approval, clinical trials and commercialization.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10577", "attributes": { "award_id": "1C06OD034103-01", "title": "Expansion and modification of animal housing and support spaces to increase production of the NIH U42 supported pigtailed macaque colony at Johns Hopkins University", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 11602, "first_name": "GUANGHU", "last_name": "Wang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-20", "end_date": "2027-05-31", "award_amount": 5500152, "principal_investigator": { "id": 24155, "first_name": "Eric Kenneth", "last_name": "Hutchinson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "In the face of well-documented ongoing shortages of nonhuman primates for biomedical research and evidence that they may be a unique model for COVID-19, it is no surprise that the demand for pigtail macaques remains strong and continues to climb. Since the onset of NIH- support in 2006, the JHU pigtail macaque colony has provided 313 animals for biomedical research, the vast majority of which was HIV/AIDS related. With 172 of those animals (55%) going to NIH funded investigators at institutions outside of JHU, we have established our colony as an important national resource of this valuable animal model. To meet the growing need for pigtail macaques in biomedical research, we have developed a plan to significantly increase the number of animals that we can house at the JHU Research Farm and further refine our behavioral management of this breeding colony to improve productivity. First, we propose to construct an addition to the existing Building 12, significantly expanding animal housing and support spaces. This new construction will include animal housing space and innovative caging for 120 additional animals across 6 harems. This addition will also house dedicated support spaces, including an operating room, radiology room, flex holding space for convalescing or pre- sale animals, and a cage washing area, along with personnel spaces such as a staff locker room with connected showers, bathroom, laundry, and PPE donning/doffing area. Second, we propose to install underground fiber optic cable and other network infrastructure to connect the JHU Research Farm facilities to high-speed internet. This project will allow us to fully leverage the soon-to-be-installed JHU-funded upgrades to 1) security and 2) electronic animal health and behavior records. If this proposal is successful, we will better serve the NIH-funded research community that relies on primate models in two key ways: 1) we will increase the number of animals available to researchers and 2) we will evaluate the novel husbandry and behavioral management features designed into the new building and share our findings with NIH-funded nonhuman primate researchers and other national breeding centers.", "keywords": [ "AIDS/HIV problem", "Animal Housing", "Animal Model", "Animals", "Area", "Behavioral", "Biomedical Research", "Breeding", "COVID-19", "Communities", "Farm", "Fiber Optics", "Funding", "Health behavior", "Human Resources", "Institution", "Internet", "Macaca nemestrina", "Modeling", "Modification", "Network Infrastructure", "Operating Rooms", "Primates", "Production", "Productivity", "Radiology Specialty", "Records", "Research", "Research Personnel", "Resources", "Sales", "Security", "Speed", "United States National Institutes of Health", "Universities", "design", "improved", "innovation", "nonhuman primate", "novel" ], "approved": true } }, { "type": "Grant", "id": "10579", "attributes": { "award_id": "1DP2AI171139-01", "title": "Spatial-Temporal Dissection of Stratified Host Tissue Responses to Severe acute respiratory syndrome-related coronaviruses in situ to Understand Intra-host Pathogenesis", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 26420, "first_name": "MARY KATHERINE", "last_name": "Bradford", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-06", "end_date": "2027-08-31", "award_amount": 372900, "principal_investigator": { "id": 26599, "first_name": "Sizun", "last_name": "Jiang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 771, "ror": "https://ror.org/04drvxt59", "name": "Beth Israel Deaconess Medical Center", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Distinctive host-pathogen interactions and adaptations are the cornerstones of co-evolution between eukaryotes and their viral pathogens. Given the rapid replication and mutation rates of RNA viruses within their host, understanding these intra-host interactions in their native tissue context is central to developing next-generation anti-viral and vaccines. The ongoing COVID-19 pandemic continues to thwart eradication due to SARS-CoV-2 Variants of Concern (VoC), where even minor changes to the spike protein can affect cellular entry, antibody neutralization, vaccine efficacy and immune responses, thus leading to immune escape. Why do these variants, along with other Severe acute respiratory syndrome–related coronaviruses (SARSr-CoVs), differ in their host pathogenesis, and how do they achieve that? Are there differential host factors or responses that influence tissue-specific tropism? These questions need to be answered with controlled experimental approaches to dissect and deconvolute the coevolutionary viral-host interactions in situ. This proposal seeks to combine powerful reverse genetics systems, next-generation tissue imaging platforms and robust animal models towards the systematic determination of host immune responses, virus evasion strategies and both inter- and intra-host viral dynamics. We propose to use these powerful methodologies to first determine host tissue responses to individual VoCs within human COVID-19 autopsies and non-human primate necropsies. Next, we seek to combine spatial-lineage tracing with tagged SARS-CoV-2 VoCs and other SARSr-CoVs that use ACE2 for entry in the humanized ACE2-K18 mouse model. To recapitulate intra-host viral variation in vivo, we will engineer these viruses to include a short sequence of peptides encoding unique barcodes. Each set of barcodes corresponds to a specific virus strain or variant. Infection of humanized ACE2 mice with a pool of these barcoded viruses, coupled with antibody or hybridization-based spatial readouts and single-cell characterization of host immune responses, will enable a methodical approach towards the systems-level investigation of intra-host viral variation and competition dynamics. The spatial framework and conceptual advances resulting from this work are applicable to a broad myriad of other biological systems and diseases, thus paving the way to better- designed therapeutics and rapid responses to understand, control and eventually eradicate new biological threats.", "keywords": [ "2019-nCoV", "ACE2", "Address", "Affect", "Animal Model", "Antibodies", "Autopsy", "Bar Codes", "Biological", "Biological Models", "COVID-19", "COVID-19 pandemic", "Cancer Biology", "Cells", "Cessation of life", "Clinical", "Communicable Diseases", "Computing Methodologies", "Coronavirus", "Coupled", "Data Analyses", "Developmental Biology", "Disease", "Disease model", "Dissection", "Engineering", "Epitopes", "Eukaryota", "Evolution", "Host Defense", "Human", "Imaging technology", "Immune", "Immune response", "Immune system", "In Situ", "Individual", "Infection", "Infectious Agent", "Integration Host Factors", "Investigation", "K-18 conjugate", "Methodology", "Methods", "Minor", "Modeling", "Molecular Virology", "Mus", "Mutation", "Nucleic Acids", "Pathogenesis", "Proteins", "RNA Viruses", "Research Proposals", "Rodent", "SARS-CoV-2 variant", "Sampling", "Severe Acute Respiratory Syndrome", "System", "Technology", "Therapeutic", "Tissue imaging", "Tissues", "Tropism", "Variant", "Viral", "Viral Pathogenesis", "Viral Vaccines", "Virus", "Virus Diseases", "Work", "base", "biological systems", "combinatorial", "data integration", "design", "imaging platform", "in situ imaging", "in vivo", "innovation", "insight", "mouse model", "neutralizing antibody", "new technology", "next generation", "nonhuman primate", "novel", "pathogen", "pathogenic virus", "prevent", "protein aminoacid sequence", "response", "reverse genetics", "theories", "tissue tropism", "vaccine efficacy", "variants of concern" ], "approved": true } }, { "type": "Grant", "id": "10581", "attributes": { "award_id": "1R01MD018343-01", "title": "LatiNET, a Multilevel Social Network Model to Examine and Address SARS-CoV-2 Misinformation in Low-Income Latinx Communities.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 24617, "first_name": "ARIELLE SAMANTHA", "last_name": "Gillman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-20", "end_date": "2027-05-31", "award_amount": 777784, "principal_investigator": { "id": 26603, "first_name": "Mariano Juan", "last_name": "Kanamori Nishimura", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 872, "ror": "", "name": "UNIVERSITY OF MIAMI SCHOOL OF MEDICINE", "address": "", "city": "", "state": "FL", "zip": "", "country": "United States", "approved": true }, "abstract": "LatiNET will use a multilevel social network model to examine how SARS-CoV-2 misinformation and Conspiracy Theory (CT) messages are shared across five settings (friends, family, work, health service and influencers), impacting Latinx vaccine hesitancy. Social networks are self-organizing social systems that create and reinforce perceptions, both positive and negative. An important gap in current knowledge relates to the content, context and communication direction about SARS-CoV-2 misinformation and CT messages. By learning how Latinx social network structures hinder or promote SARS-CoV-2 misinformation and CT messages, we will inform the design of interventions that will reduce mistrust/fear and provide correct, timely, and comprehensive information, through multiple social network sources, enabling Latinx to make the best health decisions for themselves and their families. LatiNET will focus on low-income Latinx, which have long struggled with social, economic and health inequalities. Miami-Dade County, Florida will be the site for this study, where almost 100% of residents from in wealthiest areas have received at least one SARS-CoV-2 vaccine dose while fewer than a third of residents in poorer communities, mainly inhabited by Latinx individuals, have been vaccinated.1 We have also identified that misinformation and CT messages are prevalent in Florida.2 We will use Dr. Kanamori’s (PI) K99/R00 social network approaches3-8 and Drs. Uscinski’s and Stoler’s (Co-Is) misinformation and CT message framework2,9-11 to identify how network structures and dynamics introduce and spread misinformation and CT messages that could then influence Latinx vaccine hesitancy. We will also identify network structures and dynamics that promote discussion against SARS-CoV-2 misinformation and CT messages. LatiNET will study: 1) participants’ characteristics, 2) 624 friendship sociocentric networks, 3) 1,872 egocentric networks (family, work and health service), and 4) influencer networks, all of which will be part of our adapted NIMHD framework.12 Our AIMS are: 1) Determine how network structures and dynamics inside Latinx friendship networks shape the spread and adoption of misinformation and CT messages associated with SARS-CoV-2 vaccine hesitancy. 2) Distinguish homophily and dyadic characteristics and dynamics associated with misinformation and CT messages shared with family members, co-workers and health service providers. 3) Identify Latinx affiliations with community, celebrity, public health, political influencer and communication channels that spread CT and anti-CT messages. In all AIMS, we will also study the underlying social and structural factors associated with Latinx health decision-making (e.g., discrimination, stigma, intimate partner violence) and beliefs and behaviors tied to misinformation and CT messages (e.g., individual-level political, psychological, and social factors). LatiNET will provide new information that can inform policy and the design of future interventions to reduce the impact of misinformation and CT messages on SARS-CoV-2 vaccine hesitancy nationwide, and also with different priority populations.", "keywords": [ "2019-nCoV", "Address", "Adoption", "Area", "Behavior", "Belief", "COVID-19 vaccine", "Characteristics", "Communication", "Communities", "Contracts", "County", "Decision Making", "Discrimination", "Disease", "Dose", "Economics", "Emotional Bonds", "Family", "Family member", "Florida", "Frequencies", "Friends", "Friendships", "Fright", "Future", "Health", "Health Services", "Individual", "Influentials", "Intervention", "Knowledge", "Language", "Latinx", "Latinx population", "Learning", "Low income", "Medical", "Misinformation", "National Institute on Minority Health and Health Disparities", "Network-based", "Participant", "Pathway Analysis", "Perception", "Policies", "Political Factor", "Politics", "Population", "Predisposition", "Psychological Factors", "Public Health", "SARS-CoV-2 negative", "Science", "Seeds", "Shapes", "Site", "Social Network", "Source", "Structural Racism", "Structure", "Symptoms", "System", "Testing", "Time", "Trust", "Vaccinated", "Vaccination", "Work", "cohesion", "cultural values", "design", "economic disparity", "experience", "health disparity", "health inequalities", "health services network", "intimate partner violence", "member", "network models", "pandemic disease", "poor communities", "pressure", "psychologic", "recruit", "service providers", "social", "social disparities", "social factors", "social stigma", "social structure", "sociodemographics", "theories", "therapy design", "unvaccinated", "vaccine hesitancy" ], "approved": true } }, { "type": "Grant", "id": "10582", "attributes": { "award_id": "1R56HL164737-01", "title": "Efficacy of a novel web-based physical activity intervention designed to promote adherence to physical activity guidelines in adults with obesity", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 8616, "first_name": "Laurie Friedman", "last_name": "Donze", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-09", "end_date": "2023-08-31", "award_amount": 792307, "principal_investigator": { "id": 26604, "first_name": "jacob kigo", "last_name": "kariuki", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 848, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "Project Title: Efficacy of a novel web-based physical activity intervention designed to promote adherence to physical activity guidelines in adults with obesity Funding organization: The National Heart, Lung, and Blood Institute (NHLBI) Grant type: R01 Date submitted: Oct 2, 2021 Amount requested: $3,167,589 PI: Kariuki Jacob, PhD Co-investigators: Lora E. Burke, PhD, MPH; Bethany Gibbs, PhD; Erick Erickson, PhD; Andrea Kriska. Consultants: David Ogutu, BS Project Summary/Abstract The National Guidelines recommend that all American adults achieve ≥150 min of moderate to vigorous intensity physical activity weekly. Yet, adherence to the Guidelines is low, with only 24% of adults attaining the recommended physical activity (PA). The low levels of PA increase the risk cardiometabolic disease, especially among individuals with obesity. Although any increase in PA can reduce the risk, these individuals face complex weight-related impediments including stigma, embarrassment, poor fitness, and low self-efficacy that reduce their engagement in PA. To mitigate these barriers, web-based PA interventions have been developed, but their efficacy is often limited by lack of behavioral coaching and generic content that does not address barriers experienced by those with obesity. Our research team and others have reported that culturally diverse individuals with obesity prefer PA programs that are convenient, fun to engage in, and feature people to whom they can relate especially in body size, fitness level, and age. Yet, there is a paucity of PA interventions intentionally designed to incorporate these preferences. In our prior work, we sought the input of individuals with overweight/obesity to inform the development of a technology-based Physical Activity for The Heart (PATH) intervention that leverages openly accessible platforms, such as YouTube, to provide workout videos that match the specific preferences expressed in our formative studies and the extant literature. We have successfully beta tested the PATH platform and have demonstrated excellent retention, intervention engagement and preliminary efficacy in our 12-week feasibility studies. In this application, we propose to test the efficacy of PATH in promoting adherence to the PA Guidelines in a diverse sample of inactive adults with obesity. Our long-term goal is to deploy the PATH intervention as a scalable stand-alone program to increase access, reduce time commitment, avoid weight-related stigma, and lessen the impact of unpredictable barriers to PA such as inclement weather or pandemics like COVID-19. We will conduct a 12-month 2-group randomized controlled trial and equally allocate 450 adults to one of the two intervention conditions: Path intervention or attention control. In Aim 1 we will evaluate the efficacy of PATH for improving short- and long-term adherence to the PA Guidelines. In Aim 2 we will compare the effects of the PATH intervention on risk factors for CVD. In the final Aim, we will explore the potential mechanisms of action associated with changes in the PA outcomes. At the end of the study, we will survey user experience and views on the most useful components of the PATH intervention. Our approach is innovative because we leverage freely accessible resources to provide a highly scalable, convenient, fun to engage in PA program that utilizes carefully selected workout videos to help individuals with obesity progress along the PA continuum. This contribution will be significant because PATH could offer a novel, convenient, enjoyable, and highly scalable program that features “similar others” to promote PA in adults with obesity.", "keywords": [ "Address", "Adherence", "Adult", "Age", "American", "Behavioral", "Blood Pressure", "Body Size", "COVID-19", "Cardiometabolic Disease", "Complex", "Control Groups", "Coronary heart disease", "Data", "Development", "Diabetes Mellitus", "Doctor of Philosophy", "Exercise", "Expectancy", "Face", "Feasibility Studies", "Fostering", "Funding", "General Population", "Glycosylated hemoglobin A", "Goals", "Grant", "Guidelines", "Health", "Health Promotion", "Heart", "Human", "Individual", "Informal Social Control", "Intervention", "Knowledge", "Lipids", "Literature", "Mediation", "National Heart Lung and Blood Institute", "Obesity", "Online Systems", "Outcome", "Overweight", "Persons", "Physical activity", "Prevalence", "Prevention", "Public Health", "Randomized Controlled Trials", "Regimen", "Relative Risks", "Reporting", "Research", "Research Personnel", "Resources", "Risk", "Safety", "Sampling", "Self Efficacy", "Social support", "Strenuous Exercise", "Stroke", "Surveys", "Target Populations", "Technology", "Testing", "Time", "Weather", "Weight", "Work", "adult obesity", "arm", "attentional control", "base", "cardiometabolic risk", "cardiovascular disorder risk", "cardiovascular risk factor", "compliance behavior", "dashboard", "design", "efficacy evaluation", "efficacy testing", "exercise intervention", "experience", "fitness", "flexibility", "group intervention", "high risk population", "improved", "innovation", "interest", "novel", "novel strategies", "pandemic disease", "preference", "programs", "response", "sedentary", "social stigma", "socioenvironmental factor", "success", "telecoaching", "therapy design", "translational potential", "vigorous intensity", "waist circumference", "web site", "web-based intervention" ], "approved": true } }, { "type": "Grant", "id": "10584", "attributes": { "award_id": "1R43GH002391-01A1", "title": "Development of rapid, low-cost, and high throughput COVID-19 antibody assays", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2023-03-29", "award_amount": 256131, "principal_investigator": { "id": 26609, "first_name": "Maung K", "last_name": "Khaing Oo", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1948, "ror": "", "name": "OPTOFLUIDIC BIOASSAY LLC", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "Millions have developed COVID-19 antibodies through infection or vaccines, and this number will continue to increase. However, antibodies (via infection or vaccines) decay rapidly and vary among individuals. Previous studies have shown decreased protection efficacy because of reduced antibody levels, which, in combination with muted strains, has led to recent wide spread of Delta variant (and other variants) worldwide. A third dose of vaccine is now recommended by the CDC. Regular monitoring of COVID-19 neutralizing antibodies can identify individuals requiring booster vaccines, inform incidence studies, and guide policies regarding vaccination frequency for the population. Although lateral flow assays can potentially be used for rapid COVID- 19 neutralizing antibody tests, they do not provide an accurate level of neutralizing antibodies and has large variations, making them a poor tool to track and predict susceptibility to future infections. More accurate antibody tests done at centralized labs take 2-3 days to turnaround and have a high cost ($150). OptoBio has developed a general purpose microfluidic 96-well ELISA plate (MicroFluere®) technology that reduces assay time 5-10 fold, reduces sample and reagent consumption 5-6 fold, and increases dynamic range by up to 10 fold as compared to traditional 96-well ELISA plate. The goal of Phase I study is to demonstrate the feasibility of leveraging MicroFluere® to develop an inexpensive (<$10), rapid (20 min), and high throughput (240 tests/hour) assay for COVID-19 neutralizing antibodies of different variants. Currently no product exists that is able to quantify neutralizing antibody at a high throughput and low cost at point-of-care for mass screening. There are two specific aims in Phase 1. Aim #1. Design, test, and optimize neutralizing antibody assays for 6 types of COVID-19 strains. We will first select internal standards for all 6 types of SARS-CoV-2 variants. Then we will optimize the assay parameters such as the plate surface coating, sample dilution factors, and incubation time. Finally, we will evaluate the assay performance such as recovery rate and plate-to-plate repeatability. Aim #2. Validate applicability with human blood samples and benchmark. The assay developed in Aim #1 will be tested at a BSL-2 lab at OptoBio using 75 human serum samples purchased commercially. Five other virus infections will also be included for cross-reactivity evaluation. All the results will be compared with those obtained with SARS-CoV-2 neutralizing antibody kits commercially available. In Phase II, OptoBio will test more samples and add more variants, complete a high throughput automated system, develop pre-coated MicroFluere® plates with adequate shelf lifetime, and develop assays using more convenient matrices such as finger-prick whole blood. Our envisioned product will address the unmet need for rapid, accurate, and low cost COVID-19 antibody detection at clinical labs and point-of-care testing sites. The same product and technology can also be adapted for other viral pandemics that may occur.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10585", "attributes": { "award_id": "1R21MD017662-01", "title": "A pilot clinical trial to assess feasibility, facilitators and barriers of continuous glucose monitoring in Asian Americans with type 2 diabetes", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 7440, "first_name": "DOROTHY M", "last_name": "CASTILLE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-23", "end_date": "2024-05-31", "award_amount": 255563, "principal_investigator": { "id": 26610, "first_name": "GEORGE L", "last_name": "KING", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1642, "ror": "https://ror.org/0280a3n32", "name": "Joslin Diabetes Center", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Rates of Type 2 Diabetes (T2D) are increasing both nationally and globally. In addition to known T2D complications such as retinopathy, nephropathy, neuropathy, and cardiovascular disease, T2D is known to affect cognitive impairment and even severity of COVID-19 infection. A few studies have shown the benefit of Continuous Glucose Monitoring (CGM) devices for better glycemic management in T2D populations. While prevention and management protocols for T2D are ubiquitous, there continue to exist large racial/ethnic disparities amongst the general US population. Asian Americans (AA), specifically Chinese-Americans, present with much higher T2D prevalence and face disparities in T2D care for the following reasons: 1) Stigma arising from the “model minority myth”, exacerbated by the rise in anti-Asian sentiments during the COVID-19 pandemic; 2) Higher T2D unawareness rate; 3) Cultural and language barriers including limited digital literacy and English proficiency; and 4) Historical exclusion from T2D studies, including those on CGM devices and T2D, in which culturally-relevant facilitators and barriers to CGM use have yet to be evaluated in AAs. This study will specifically examine how T2D could be better managed in Chinese Americans through a CGM intervention, as compared to standard fingerstick glucose monitoring (FSGM). We will be conducting a 6- month, single-site, open-labeled randomized controlled trial examining CGM versus no CGM (FSGM) use in 1st-generation Chinese Americans. Our specific aims are: Sp. Aim 1: In a pilot 6-month randomized clinical trial, we will examine the impact of CGM use vs. No CGM among 1st generation Chinese Americans with T2D. Sub-Aim 1.1. Evaluate feasibility (adherence and consistency) and quality of life measures during CGM use in this population. Sub-Aim 1.2. Generate precision estimates of the distribution of the secondary outcomes (6- month glycemic control and lipid markers) in both arms to inform a future randomized clinical trial (RCT). Sp. Aim 2: Identify multi-level barriers and facilitators of CGM use for Chinese Americans with T2D, using a socioecological framework (patient-level, provider-level, and community/environment level). We will evaluate the implementation process (facilitators and impediments), resource requirements, and intermediate patient adherence outcomes for the program using mixed-methods approaches. These will inform design of culturally- tailored intervention for a larger randomized controlled trial.", "keywords": [ "Address", "Adherence", "Advocacy", "Affect", "Age", "Asian", "Asian Americans", "Body mass index", "COVID-19 pandemic", "COVID-19 severity", "Cardiovascular Diseases", "Caring", "China", "Chinese", "Chinese American", "Clinical Trials", "Communities", "Complications of Diabetes Mellitus", "Data", "Diabetes Mellitus", "Diagnosis", "East Asian", "Education", "Environment", "Ethnic group", "Exclusion", "Face", "Future", "Generations", "Guidelines", "Health", "Health Technology", "Healthcare", "Immigrant", "Impaired cognition", "Intervention", "Japanese", "Kidney Diseases", "Koreans", "Language", "Limited English Proficiency", "Link", "Lipids", "Measures", "Medicaid", "Medicare", "Metabolic", "Methods", "Minority", "Modeling", "National Health and Nutrition Examination Survey", "Neuropathy", "Non-Insulin-Dependent Diabetes Mellitus", "Not Hispanic or Latino", "Outcome", "Participant", "Patients", "Population", "Prevalence", "Prevention", "Protocols documentation", "Provider", "Quality of life", "Race", "Randomized Clinical Trials", "Randomized Controlled Trials", "Reporting", "Resources", "Retinal Diseases", "SARS-CoV-2 infection", "Site", "South Asian", "Subgroup", "Technology", "Uninsured", "Variant", "arm", "compliance behavior", "cost", "design", "diabetes risk", "digital", "ethnic minority", "glucose monitor", "glycemic control", "health care disparity", "implementation evaluation", "implementation process", "implementation strategy", "innovation", "literacy", "monitoring device", "open label", "pandemic disease", "policy implication", "programs", "racial and ethnic disparities", "secondary outcome", "sex", "skills", "social health determinants", "social stigma", "southeast Asian", "tool", "vocalization" ], "approved": true } }, { "type": "Grant", "id": "10588", "attributes": { "award_id": "1G20AI174723-01", "title": "BSL3 Enhancements for RNA Virus Pandemic Preparedness", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 24445, "first_name": "Nancy G.", "last_name": "Boyd", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-16", "end_date": "2024-02-29", "award_amount": 3994219, "principal_investigator": { "id": 26614, "first_name": "Hardy", "last_name": "Kornfeld", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 790, "ror": "", "name": "UNIV OF MASSACHUSETTS MED SCH WORCESTER", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Program Summary/Abstract The University of Massachusetts Chan Medical School (UMass Chan) seeks NIH G20 funding to repair, renovate, and modernize the existing Biosafety Level 3 (BSL3) and Animal BSL3 (ABSL3) facilities to enhance current research on RNA viruses of pandemic potential. As an internationally recognized leader in infectious disease research, UMass Chan has made pivotal contributions to this field, including work on the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), highly pathogenic avian influenza virus, Newcastle disease virus, and Zika virus. At the start of the coronavirus 2019 (COVID-19) pandemic, we quickly became one of the leading institutes for research and clinical trials on SARS-CoV-2. Our researchers obtained several awards from the NIH, NSF, and Department of Defense, as well as private foundations for these studies. As a leading site for COVID-19 clinical trials, UMass Chan is uniquely poised to bridge clinical and basic research studies on these RNA viruses by enabling essential research on patient samples to complement in vitro and in vivo studies. Our findings can be translated to develop novel prevention and therapeutic strategies leveraging our world-renowned RNA Therapeutics Institute, our Institute for Drug Resistance, and our partnership with MassBiologics for vaccine development, making UMass Chan a powerhouse for bench-to-bedside translational research. The UMass Chan BSL3 Core Laboratories have seen a staggering increase in usage due to the pandemic. Our BSL3 and ABSL3 facilities need major updates and renovations to keep pace with our research programs and continue to provide a safe, modern, and efficient lab for BSL3 work. The last time these facilities were completely renovated was over a decade ago (2003–2005 for our ABLS3 and 2010–2014 for our BSL3). We will modernize the existing BSL3 and ABSL3 facilities by updating the ceiling and ventilation systems, installing new autoclaves, maximizing the existing footprint by removing outdated equipment, and updating cameras for safety. These updates will significantly enhance research on RNA viruses of pandemic potential by addressing deficiencies that have caused prolonged downtime for repairs, and by enhancing the resilience of critical building systems. Our UMass Chan Facilities and Campus Services team has extensive experience executing design, renovations, and oversight of the operations and have worked with the NIH on previous G20 and C06- funded improvements to our facilities. The G20 funding will also be backed by strong institutional support for this project and a commitment to fully equip the updated space with state-of-the-art scientific instruments and other equipment needed to maintain the productivity of currently funded and future research on SARS-CoV-2 and other BSL3-level RNA viral pathogens. With G20 funding, our BSL3 and ABSL3 labs can get much- needed updates to support our faculty as they continue to make ground-breaking fundamental discoveries with translational potential to address SARS-CoV-2 and other RNA viruses of pandemic potential.", "keywords": [ "2019-nCoV", "Address", "Air", "Alphavirus", "Ambulatory Care", "Animals", "Avian Influenza A Virus", "Award", "Back", "Basic Science", "Biotechnology", "COVID-19", "COVID-19 pandemic", "Carbon Dioxide", "Chikungunya virus", "Clinical Research", "Clinical Trials", "Communicable Diseases", "Communication", "Complement", "Coronavirus", "Department of Defense", "Drug resistance", "Ensure", "Equipment", "FDA approved", "Faculty", "Foundations", "Freezing", "Funding", "Goals", "Hamsters", "Hantavirus", "Housing", "Immune", "Immunoglobulin A", "In Vitro", "Incubators", "Infectious Diseases Research", "Innovative Therapy", "Institutes", "Institution", "Integration Host Factors", "International", "Laboratories", "Manuscripts", "Massachusetts", "Modernization", "Nature", "Newcastle disease virus", "Pathogenicity", "Patients", "Positioning Attribute", "Prevention", "Prevention strategy", "Privatization", "Procedures", "Productivity", "Protocols documentation", "RNA", "RNA Viruses", "RNA vaccine", "Research", "Research Institute", "Research Personnel", "Research Project Grants", "Resources", "SARS coronavirus", "SARS-CoV-2 pathogenesis", "Safety", "Sampling", "Security", "Services", "Site", "Structure", "System", "Therapeutic", "Time", "Translating", "Translational Research", "United States National Institutes of Health", "Universities", "Update", "Virus Diseases", "Virus-like particle", "Work", "Zika Virus", "base", "bench to bedside", "biosafety level 3 facility", "cost", "design", "experience", "hemorrhagic fever virus", "humanized mouse", "in vivo", "innovation", "instrument", "medical schools", "member", "mouse model", "novel", "operation", "pandemic disease", "pandemic preparedness", "pathogen", "pathogenic bacteria", "pathogenic virus", "programs", "recruit", "repaired", "research study", "resilience", "square foot", "therapeutic RNA", "translational potential", "translational study", "treatment strategy", "vaccine development", "vaccine strategy", "ventilation" ], "approved": true } }, { "type": "Grant", "id": "10589", "attributes": { "award_id": "1R01DK131410-01A1", "title": "The impact of COVID-19 pandemic-related stressors on childhood obesity and cardiometabolic risk", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)" ], "program_reference_codes": [], "program_officials": [ { "id": 26615, "first_name": "Barbara", "last_name": "Linder", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-19", "end_date": "2026-06-30", "award_amount": 671427, "principal_investigator": { "id": 26616, "first_name": "Alicia S", "last_name": "Kunin-Batson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 764, "ror": "https://ror.org/017zqws13", "name": "University of Minnesota", "address": "", "city": "", "state": "MN", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID-19 pandemic has had an alarming impact on already unacceptably high childhood obesity rates, and emerging evidence shows that traditional approaches to pediatric weight management have been markedly less effective since the onset of the pandemic. As obesity during childhood is much more likely to be sustained during adulthood, and children with obesity and other chronic conditions are more likely to have severe forms of COVID-19 requiring hospitalization, this alarming increase in childhood obesity rates is poised to have a broad and long-term impact on population health unless effective interventions are implemented. Yet, we know very little about the unique drivers of this dramatic increase in childhood obesity and whether BMI increases will persist and become lifelong. We know even less about the protective factors that mitigate this risk, as some youth will not develop obesity/worsening cardiometabolic health or may recover quickly despite risk exposures. Our goals are to uncover the biobehavioral pathways through which pandemic-related stressors drive childhood obesity and cardiometabolic risk, and to identify protective factors and intervention targets to mitigate the long-term impact of the pandemic on children’s health. The proposed research offers a unique, time-sensitive opportunity to prospectively examine the impact of multilevel stressors brought on by the pandemic to identify factors influencing BMI and cardiometabolic health trajectories. We will leverage an established longitudinal cohort of racially/ethnically diverse children (60% Latino) from predominantly low- income households, who were enrolled at 2-4 years of age (U01HD068890) and followed annually through ages 7-11 (R01HD090059). Underscoring the timeliness, uniqueness, and significance of this cohort, body composition, cardiovascular and metabolic functioning, neuroendocrine, oxidative stress, and inflammatory biomarkers, and health behaviors were obtained just prior to the onset of the pandemic (n=338). Drawing on a rich history of longitudinal data over 5 previous timepoints including immediately prior to the pandemic, we propose to add two new waves of data collection (7- and 8-years after inception of the cohort, 2-3 years post- onset of the pandemic) when children will be 10-14 years of age, an important developmental window of obesity and cardiometabolic imprinting. Multiple levels of pandemic-related stressors will be measured, alongside gold standard biological measures of stress activation, adiposity and cardiometabolic health, objective health behavior measures, and parent-child surveys. Our specific aims focus on identifying the pathways, parent-child factors, and neighborhood/community contexts needed to guide effective childhood obesity interventions in the aftermath of the pandemic and reduce adverse health consequences among vulnerable and understudied populations.", "keywords": [ "14 year old", "4 year old", "Adult", "Affect", "African American", "Age", "Behavioral Mechanisms", "Biological", "Biological Markers", "Body Composition", "Body fat", "Body mass index", "Buffers", "COVID-19", "COVID-19 pandemic", "COVID-19 pandemic effects", "Cardiovascular system", "Cell Aging", "Child", "Child Health", "Child Rearing", "Childhood", "Chronic", "Clinical", "Communities", "Data", "Data Collection", "Development", "Disease Outbreaks", "Economics", "Energy Intake", "Enrollment", "Ethnic Origin", "Exhibits", "Future", "Goals", "Gold", "Health", "Health behavior", "Heel", "Hospitalization", "Household", "Hydrocortisone", "Inadequate Sleep Hygiene", "Income", "Inflammation", "Inflammatory", "Intervention", "Job loss", "Latino", "Longitudinal cohort", "Low income", "Measures", "Mediating", "Mental Health", "Metabolic", "Neighborhoods", "Neurosecretory Systems", "Obesity", "Outcome", "Overweight", "Oxidative Stress", "Parents", "Pathway interactions", "Physical activity", "Policies", "Population", "Prevalence", "Race", "Recording of previous events", "Reducing diet", "Research", "Resources", "Risk", "Schools", "Security", "Self Efficacy", "Social Network", "Social isolation", "Stress", "Surveys", "Time", "Weight maintenance regimen", "Youth", "base", "biobehavior", "cardiometabolic risk", "cardiometabolism", "cohort", "effective intervention", "ethnic diversity", "executive function", "experience", "food insecurity", "housing instability", "imprint", "obesity in children", "obesity risk", "obesity treatment", "pandemic disease", "population health", "prevent", "prospective", "protective factors", "psychosocial stressors", "public health priorities", "racial and ethnic", "resilience", "response", "stressor", "trend", "tv watching" ], "approved": true } }, { "type": "Grant", "id": "10590", "attributes": { "award_id": "1R01EB031030-01A1", "title": "SOCAL: Privacy-protecting Sharing Of Clinical Data Across Laboratories", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [ { "id": 24105, "first_name": "Grace", "last_name": "Peng", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-30", "end_date": "2026-06-30", "award_amount": 328388, "principal_investigator": { "id": 26617, "first_name": "Tsung-Ting", "last_name": "Kuo", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 760, "ror": "https://ror.org/0168r3w48", "name": "University of California, San Diego", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Privacy and security of personal information has become one of the major grand challenges in modern society, especially for healthcare studies. Re-identification risks and data breaches require new policies and regulations for data sharing across healthcare institutions and research laboratories. While policy cannot solve the problem on its own, advanced technologies that work hand in hand with policy are important to address the privacy/security concerns. Predictive analytics can support quality improvement, clinical research, and eventually impact patient health status. Extensive clinical variable information and voluminous data records from multiple institutions and laboratories are necessary to further improve the performance of modeling approaches and to identify medication-outcome associations for diseases. Nonetheless, the transfer of such sensitive data among institutions/laboratories can present serious privacy risks, which can jeopardize NIH’s mission. Aiming at mitigating the privacy problem while increasing predictive capability via cross-institutional modeling, prior studies proposed distributed methods to exchange only the predictive models, but not patient data. However, these methods still pose many challenges to the clinical cross-institutional learning problem, including the need for more comprehensive clinical variables and more patient records to achieve better prediction discrimination and build more generalizable models, the necessity for discovery/alleviation of data manipulation to increase the trustworthiness of the collaboratively trained models, and the requirement for more validation to ensure usability. In this proposal, we plan to develop SOCAL (Privacy-protecting Sharing Of Clinical data Across Laboratories), a distributed framework addressing these challenges by integrating vertical/horizontal modeling methods to include both more complete variables and more records, discovering/alleviating data manipulation incidents using models recorded on blockchain, and conducting controlled experiments and designing/testing a web portal with physician-researchers to increase the usability of the system. SOCAL will be evaluated on a Coronavirus Disease 2019 (COVID-19) dataset from five University of California (UC) Health medical centers. We expect the knowledge/capability of collaborative modeling can be improved, the trustworthiness of the learning process can be enhanced, and the framework will be ready for use. SOCAL is innovative because it will be a new integration methodology for vertical/horizontal modeling, a novel data manipulation resisting methods, and a hardened prototype for a practical blockchain application. We anticipate a powerful impact of the SOCAL framework to largely reduce the privacy concerns of predictive modeling tasks for various stakeholders, including healthcare providers, clinical researchers, and patients. Upon completion, SOCAL can accelerate the development of methods/technologies to increase willingness of institutions to participate in such a collaboration for improving the effectiveness of healthcare.", "keywords": [ "Address", "Artificial Intelligence", "COVID-19", "California", "Clinical", "Clinical Data", "Clinical Research", "Collaborations", "Data", "Data Set", "Decentralization", "Discrimination", "Disease", "Effectiveness", "Electronic Health Record", "Ensure", "Extravasation", "Failure", "Health", "Health Personnel", "Health Status", "Healthcare", "Hospitals", "Institution", "Intuition", "Knowledge", "Laboratories", "Laboratory Research", "Learning", "Machine Learning", "Medical center", "Methodology", "Methods", "Mission", "Modeling", "Modernization", "Outcome", "Patients", "Performance", "Pharmaceutical Preparations", "Physicians", "Policies", "Predictive Analytics", "Primary Care Physician", "Privacy", "Problem Solving", "Process", "Protocols documentation", "Records", "Regulation", "Research Personnel", "Risk", "Security", "Site", "Societies", "System", "Technology", "Testing", "Training", "United States National Institutes of Health", "Universities", "Validation", "Work", "base", "blockchain", "care providers", "data sharing", "data warehouse", "design", "experimental study", "health care quality", "improved", "innovation", "learning strategy", "method development", "novel", "peer", "predictive modeling", "privacy preservation", "prototype", "trustworthiness", "usability", "web portal", "willingness" ], "approved": true } } ], "meta": { "pagination": { "page": 1384, "pages": 1392, "count": 13920 } } }